Diaceutics, the diagnostics data analytics and implementation services company, has reported revenues of £4.4m for the six months to the end of June.
This marked an increase of 34% on the £3.3m reported the same time last year.
The Northern Ireland-based company, which floated on London's AIM market in March, also reported a loss before tax of £2m.
It said this reflected exceptional IPO related costs of £1.4m.
The company said it had a strong balance sheet with net cash of £14m at the end of June compared to net debts of £0.9m the same time last year.
Diaceutics said it now supports 38 therapy brands in 16 markets, an increase of 73% from the first half of 2018. It also said the number of clients increased by 35% from 20 to 27.
During the six month period, the company said it also continued to expand its geographic reach, particularly in Asia.
Peter Keeling, the company's CEO, said Diaceutics decided to move to AIM to continue its growth trajectory by developing its product and services offering which is focused on better testing and better treatment in the global pharmaceutical industry.
"We have seen good growth since we came to market and continue to work hard on expanding the data lake and increasing our international footprint," Mr Keeling said.
He also reaffirmed that company's outlook for the year remains unchanged.
